Navigation Links
Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
Date:10/29/2008

VYVANSE is the first oral ADHD stimulant medication with published data demonstrating symptom control at 13 hours post-dose in a pediatric clinical study

CHICAGO, Oct. 29 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced results from a 13-hour analog classroom study in school-aged children aged 6 to 12 years with Attention Deficit Hyperactivity Disorder (ADHD). In this study, researchers found that VYVANSE controlled ADHD symptoms from the first time point measured (1.5 hours) through the last time point assessed (13 hours) post-dose. Findings from this analog classroom study were presented today at a national psychiatric meeting in Chicago.

"The study presented today is the first published data demonstrating improvements in attention and behavior with an oral ADHD stimulant treatment for up to 13 hours post-dose," said Ann C. Childress, MD, study investigator, president of the Center for Psychiatry and Behavioral Medicine, Inc. in Las Vegas, and volunteer assistant professor of psychiatry at the University of Nevada School of Medicine in Las Vegas. "In this study, once-daily VYVANSE significantly improved attention and behavior at 1.5 hours after a morning dose of the medication and continued to do so for each time point measured throughout the 13-hour treatment day. These findings are significant because children with ADHD require symptom control that lasts throughout the school day as well as after-school hours."

This study confirms the results of a previous clinical trial in which VYVANSE demonstrated ADHD symptom control throughout a 12-hour treatment day. The adverse events in the 12-hour study for patients taking Vyvanse during the double-blind treatment period that were greater than or equal to 2 percent were insomnia, decreased appetite, and anorexia.

"This is encouraging news for physicians and patients seeking a long-acting ADHD treatment option
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
2. Wyeth Applauds Six Countries Across Europe, and the Middle East, That Recently Announced the Inclusion of the 7-Valent Pneumococcal Conjugate Vaccine (PCV7) in Their Immunization Schedules
3. Marketing of Diagnostics and deCODEme(TM), Recent Progress in Drug Development to be Highlighted at deCODE R&D Event
4. Presentations From Recent Heart Rhythm Society Meeting Validate the Safety and Efficacy of Ablation Frontiers Technology in 230 Patients
5. New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
6. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
7. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
8. Recent Data Study Suggests Cortisol Could Help Alleviate Suffering for Those With Chronic Fatigue Syndrome and Fibromyalgia
9. Alegent Health Sees Positive Results From Recent Clinician Usability Study Collaboration With Siemens and Motion Computing
10. Recent Studies Suggest Popular Diet Pill Relacore Reduces Acne Breakouts
11. Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... England and BOSTON , May 24, ... discovery and development company, is pleased to announce that it has ... to augment the Company,s business development capabilities in Japan ... more than 15 years of experience in business development, licensing and ... Sciences, Inc., Roche Pharma ( Japan ), Nippon Roche ...
(Date:5/23/2013)... y PARÍS, 24 de mayo de 2013 /PRNewswire/ ... destacado desarrollador y fabricante de herramientas de precisión ... y tratamiento de la enfermedad vascular periférica y ... ADVISE ( Ad enosine V asodilator ... II durante la sesión de ensayo clínico hot ...
(Date:5/23/2013)... BRAINTREE, Mass. , May 23, 2013  Haemonetics Corporation ... Chris Lindop , CFO & EVP-Business Development, will present ... Care Conference in Boston, MA on ... (Logo: http://photos.prnewswire.com/prnh/20120206/NE47232LOGO ) The public may ... About Haemonetics Haemonetics (NYSE: ...
Breaking Medicine Technology:Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... Campath May Lead to Overall Survival in Patients with Poor ... FRANCISCO, Dec. 9 Bayer HealthCare Pharmaceuticals Inc. today announced ... showed activity in high-risk chronic lymphocytic leukemia (CLL) patients who ... 50th Annual Meeting of the American Society of Hematology in ...
... 8 Millennium: The Takeda Oncology Company today ... of patients from the large, international Phase III ... with previously untreated multiple myeloma given VELCADE, melphalan ... efficacy in all patient sub-groups, including those with ...
Cached Medicine Technology:Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 2Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 3Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 4Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 5Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 6Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 7Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 8Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 9Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 10Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 2Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 3Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 4Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 5Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 6
(Date:5/24/2013)... 24, 2013 Bridal Buy , ... announce new 2013 bridesmaid dresses are available ... dresses are handcrafted, featured as fine fabrics, elegant beading, ... takes great skill and an eye for detailed designs. ... embroidery, brought to life from patterns and the hands ...
(Date:5/24/2013)... 24, 2013 IMED Mobility, a premier provider of ... by Nashville recording artist Michelle Murray on Thursday, June 20th 2 ... “My Finish Line” music and movie tour, which shares the story ... crash on the track in 2000. Much of the film takes ... for the sport of INDYCAR racing despite suffering a crash that ...
(Date:5/23/2013)... May 24, 2013 Magnatag’s new magnetic ... patterns and reduces vacation conflicts. A Manufacturing Manager from ... vacation conflicts; now employees and managers can check the ... problems. Attendance is important to us and the board ... That may seem harsh but it has made a ...
(Date:5/23/2013)... Maui, HI (PRWEB) May 23, 2013 Magic ... comic book describing the exploits of precocious twin five-year olds, ... Maui , is just such a case in point. May ... Maui” and is timed to coincide with the start ... travel experience combining family adventures, tons of amenities and, most ...
(Date:5/23/2013)... May 23, 2013 Whether working in ... Forces and law enforcement need an added layer of ... Enhancer, Night VISER , is an effective portable, ... sensing system to increase border and perimeter security. , ... have more than tripled over the past three years, ...
Breaking Medicine News(10 mins):Health News:Local Mobility Dealer Hosts Nashville Recording Artist 2Health News:New Attendance, Vacation and Training Tracker Board Reduces Employee Conflicts and Improves Attendance 2Health News:New Children's Comic Book, "Howie Goes to Maui," Launches May 23, 2013 On Four Seasons Resort Maui's Web Site 2Health News:New Children's Comic Book, "Howie Goes to Maui," Launches May 23, 2013 On Four Seasons Resort Maui's Web Site 3Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 2Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 3
... well-being, , FRIDAY, Sept. 25 (HealthDay News) -- The bad ... points. , The good news is that it appears that ... one expert believes that part of the reason why is ... United States and elsewhere. , That,s the view of discipline ...
... ... October 31 - Sunday, November 1. Practitioner Training: Friday, October 30 , ... Buffalo, NY (PRWEB) September 25, ... of 1 in 150 children in the U.S. have an Autism Spectrum Disorder (ASD), ...
... ... of New Emergency 911 Center , ... Pittsburgh, PA (PRWEB) September 25, 2009 -- synergIT ... San Francisco the firm,s ground-breaking renovation of Washington County,s Emergency 911 call center ...
... ... upgrades to iCodeRx, iDocs, and iCharts now allow healthcare organizations to fully integrate and ... information. , ... Beach, VA (PRWEB) - DOMA Technologies ( www.domaonline.com ) has launched the latest version ...
... diet and weight are shaped by their social class, according ... Council. Policymakers have long insisted on the importance ... is the first study to show how everyday practices and ... diet, weight and health of teenagers. ,It is evident ...
... modest advantage over non-surgical therapies, researchers say , THURSDAY, ... than non-surgical treatment for patients with carpal tunnel syndrome ... has found. , The study included 44 patients who ... such as hand therapy and ultrasound. A year after ...
Cached Medicine News:Health News:Spanking May Lower Kids' IQs 2Health News:Spanking May Lower Kids' IQs 3Health News:AutismOne & Autism Canada Present "CHANGING THE COURSE OF AUTISM IN CANADA 2009" University of Toronto 2Health News:AutismOne & Autism Canada Present "CHANGING THE COURSE OF AUTISM IN CANADA 2009" University of Toronto 3Health News:synergIT Presents at VMworld 2009 in San Francisco 2Health News:synergIT Presents at VMworld 2009 in San Francisco 3Health News:DOMA Transforms Healthcare IT with Increased Security While Reducing Cost -- iCodeRx/iDocs/iCharts 6.0 Debuts at AHIMA National Convention 2Health News:DOMA Transforms Healthcare IT with Increased Security While Reducing Cost -- iCodeRx/iDocs/iCharts 6.0 Debuts at AHIMA National Convention 3Health News:Social background weighs heavily on teenage diet 2Health News:Surgery Best for Carpal Tunnel Syndrome 2Health News:Surgery Best for Carpal Tunnel Syndrome 3
... of Surgical Access ...unlike any trocar system ... system is actually four systems in one ... and clinically adaptive to all of your ... and bladed or dilating tip styles, OnePort™ ...
... Pak contains: (1) 15mm obturator, ... (1) 12mm ENDOPATH thoracic trocar ... Pak contains: (1) 15mm obturator, ... ,FPK03 Thoracic Trocar Pak contains: ...
... ENDOPATH Dilating Tip Trocar is a full-featured trocar ... a spring-loaded blade shield. The shield is designed ... internal structures from puncture or laceration once the ... integrated stability sleeve option is designed to enhance ...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Medicine Products: